The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksADAM.L Regulatory News (ADAM)

  • There is currently no data for ADAM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of SPA with Infinity Capital Group

15 Nov 2019 07:00

RNS Number : 4996T
Adamas Finance Asia Limited
15 November 2019
 

15 November 2019

ADAMAS FINANCE ASIA LIMITED

(the "Company" or "ADAM")

Completion of the share sale and purchase agreement with Infinity Capital Group Limited

Further to its announcement on 21 October 2019, Adamas Finance Asia Limited (AIM: ADAM), the London quoted company focused on providing shareholders with attractive uncorrelated, risk adjusted returns from a diversified portfolio of pan-Asian investments, is pleased to announce that all conditions precedent in relation to the proposed equity investment in Infinity TNP have been fulfilled and the share sale and purchase agreement ("SPA") has now completed.

 

As agreed in the SPA, the Company today issued Infinity Capital Group Limited, parent of Infinity TNP, 16,179,310 new ordinary shares in the Company at a price of 34.8p per ordinary share (the "Consideration Share Price"). The Consideration Share Price represents a premium of 20% to the 30-day weighted average price per share in ADAM immediately prior to the execution of the SPA.

 

Application has been made for the new ordinary shares issued to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective on 20 November 2019.

 

Following Admission, the Company's enlarged issued share capital will comprise 104,912,379 ordinary shares. The Company holds 916,804 shares in treasury. The total voting rights in the Company are 103,995,575 ordinary shares. This figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

For further information, please visit the Company's website at http://adamasfinance.com and follow the Company on Twitter (@AdamasFinance).

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

Adamas Finance Asia Limited

+44 (0) 1825 830587

John Croft

WH Ireland Limited - Nominated Adviser

+44 (0) 20 7220 1666

James Joyce

James Sinclair Ford

Pello Capital Limited - Corporate Broker

+44 (0) 20 3700 2500

Tim Sohal

Maitland/AMO - Communications Advisor

+44 (0) 20 7379 5151

James Benjamin

Peter Hamid

 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014

 

About Adamas Finance Asia

Adamas Finance Asia Limited (ADAM) is quoted on the AIM Market of the London Stock Exchange and is committed to providing shareholders with attractive uncorrelated, risk adjusted long-term returns from a combination of realising sustainable capital growth and delivering dividend income.

 

The Company is focused on providing growth capital and financing to emerging and established Small and Medium Enterprises (SME) sector throughout Asia, well diversified by national geographies, instruments and asset classes. This vital segment of the economy is underserved by the traditional banking industry for regulatory and structural reasons.

 

The Company's investment manager, Harmony Capital, seeks to capitalise on its team's established investment expertise and broad networks across Asia. Through rigorous diligence and disciplined risk management, Harmony Capital is dedicated to delivering attractive income and capital growth for shareholders with significant downside protection through selectively investing in assets and proactively managing them.

 

Harmony Capital is predominately sourcing private opportunities and continues to create a strong pipeline of attractive income generating assets from potential investments in growth sectors across Asia, including healthcare, fintech, hospitality, IT and property. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDVZLFFKFFEFBF
Date   Source Headline
5th Dec 20169:00 amRNSDirector/PDMR Shareholding
28th Nov 201610:00 amRNSDirector/PDMR Shareholding
23rd Nov 20169:11 amRNSDirector/PDMR Shareholding
31st Oct 20168:05 amRNSDirector/PDMR Shareholding
24th Oct 20162:48 pmRNSDirector/PDMR Shareholding
17th Oct 201612:30 pmRNSDirector/PDMR Shareholding
12th Oct 20168:35 amRNSDirector/PDMR Shareholding
7th Oct 20168:45 amRNSre: redemption of Global Pharm Convertible Bond
6th Oct 20169:26 amRNSRestructuring of Investment in Fortel
29th Sep 20169:31 amRNSDirector/PDMR Shareholding
26th Sep 20167:00 amRNSReceipt of US$820,000 from GCCF
23rd Sep 20162:40 pmRNSDirector/PDMR Shareholding
16th Sep 201610:13 amRNSDirector/PDMR Shareholding
12th Sep 20168:54 amRNSHalf Yearly Report
1st Sep 20167:00 amRNSChange of Adviser
28th Jul 20164:40 pmRNSSecond Price Monitoring Extn
28th Jul 20164:35 pmRNSPrice Monitoring Extension
21st Jul 201610:26 amRNSResult of AGM
6th Jul 20167:00 amRNSGCCF successfully exits Project Media
28th Jun 20168:37 amRNSRepayment of Loan by Portfolio Company
23rd Jun 20168:22 amRNSFinal Results
6th Apr 201610:36 amRNSRealisation of Investment in BRJ
1st Apr 201611:23 amRNSGlobal Pharm Update
31st Mar 20167:00 amRNSChange of Adviser
1st Mar 20169:37 amRNSDealing by Mark Hibbs
27th Jan 20168:01 amRNSGlobal Pharm Update
15th Jan 20169:34 amRNSDirector/PDMR Shareholding
7th Jan 20163:07 pmRNSUpdate on proposed IPO of HKMH
22nd Dec 201510:56 amRNSBroker Update
4th Dec 20157:00 amRNSAdamas AM & Ping An Trust Joint Venture Fund
30th Nov 20152:30 pmRNSGlobal Pharm Update
17th Nov 201512:04 pmRNSHolding(s) in Company
26th Oct 201510:56 amRNSRevised Redemption Agreement with Global Pharm
21st Oct 20158:49 amRNSRevised Redemption Agreement with Global Pharm
5th Oct 20157:00 amRNSADAM to invest a further $3m in Adamas' GCCF
18th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSAdamas Strengthens its Executive Team
20th Aug 20157:00 amRNSUpdate on Disposal of Interest in Global Pharm
20th Jul 20157:00 amRNSUpdate on Disposal of Interest in Global Pharm
3rd Jul 20157:00 amRNSA1 Filing by HKMH
19th Jun 20157:00 amRNSFinal Results
15th Jun 201512:35 pmRNSUpdate on Disposal of Interest in Global Pharm
15th May 201512:09 pmRNSUpdate on Disposal of Interest in Global Pharm
29th Apr 20157:00 amRNSBroker Update
9th Apr 20158:37 amRNSAppointment of Broker
8th Apr 201510:53 amRNSResult of General Meeting
7th Apr 20154:40 pmRNSSecond Price Monitoring Extn
7th Apr 20154:35 pmRNSPrice Monitoring Extension
1st Apr 20157:00 amRNSUpdate on Disposal of Interest in Global Pharm
20th Mar 20153:11 pmRNSChange of Investing Policy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.